Steve Perrin

University Medical Pharmaceuticals (United States) — United States

Medicine · Health Sciences

12h-index3.5kcitations30works56.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(6), Monoclonal and Polyclonal Antibodies Research(5), Protease and Inhibitor Mechanisms(4), Amyotrophic Lateral Sclerosis Research(4), Tissue Engineering and Regenerative Medicine(4)

Publications30 total

Gene-edited pig cardiac xenotransplantation as a bridge to allotransplantation in infants: Progress in a pig-to-baboon model
American Journal of Transplantation·2025· 1 citedOpen Access
Xenotransplantation of a Porcine Kidney for End-Stage Kidney Disease
New England Journal of Medicine·2025· 94 cited
Transplantation of a genetically modified porcine heart into a live human
Nature Medicine·2025· 75 cited
The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates
Science Translational Medicine·2023· 43 citedOpen Access
Supplementary Table S2 from Identification of <i>SFRP1</i> as a Candidate Mediator of Stromal-to-Epithelial Signaling in Prostate Cancer
2023Open Access
Supplementary Table S1 from Identification of <i>SFRP1</i> as a Candidate Mediator of Stromal-to-Epithelial Signaling in Prostate Cancer
2023Open Access
Data from Targeting the Lymphotoxin-β Receptor with Agonist Antibodies as a Potential Cancer Therapy
2023Open Access
Supplementary Table S1 from Identification of <i>SFRP1</i> as a Candidate Mediator of Stromal-to-Epithelial Signaling in Prostate Cancer
2023Open Access
Data from Identification of <i>SFRP1</i> as a Candidate Mediator of Stromal-to-Epithelial Signaling in Prostate Cancer
2023Open Access
Supplementary Table S2 from Identification of <i>SFRP1</i> as a Candidate Mediator of Stromal-to-Epithelial Signaling in Prostate Cancer
2023Open Access
Data from Identification of <i>SFRP1</i> as a Candidate Mediator of Stromal-to-Epithelial Signaling in Prostate Cancer
2023Open Access
Supplementary Tables 1-3, Figure 1 from Targeting the Lymphotoxin-β Receptor with Agonist Antibodies as a Potential Cancer Therapy
2023Open Access
Supplementary Tables 1-3, Figure 1 from Targeting the Lymphotoxin-β Receptor with Agonist Antibodies as a Potential Cancer Therapy
2023Open Access
Data from Targeting the Lymphotoxin-β Receptor with Agonist Antibodies as a Potential Cancer Therapy
2023Open Access
Development of a classifier for [18F]fluorodeoxyglucose extravasation severity using semi-quantitative readings from topically applied detectors
EJNMMI Physics·2022· 1 citedOpen Access
QIM19-133: Assessing and Reducing FDG PET/CT Radiotracer Infiltrations: Lessons in Quality Improvement Sustainability
Journal of the National Comprehensive Cancer Network·2019
A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis
Science Translational Medicine·2018· 85 citedOpen Access
Hatzipetros et al (2013) TDP-43 A315T mouse and GI dysfunction
2016
Hatzipetros et al (2013) Supplemental info
2016
Preclinical research: Make mouse studies work
Nature·2014· 649 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Stephen E. Fawell(12), Margaret S. Joesting(7), Brian Elenbaas(7), Jeffrey S. Rubin(7), Omar E. Franco(7), Simon W. Hayward(7), Gerald R. Cunha(7), Paul C. Marker(7), Matvey Lukashev(5), Doreen LePage(5), Cheryl A. Wilson(5), Véronique Bailly(5), Ellen A. Garber(5), Alex Lukashin(5), Apinya Ngam-ek(5), Weike Zeng(5), Norman Allaire(5), Kendall T. Szeliga(5), Kathleen Wortham(5), Cindy Bottiglio(5)